Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

AIM ImmunoTech Inc. (AIM)

0.84   0.01 (1.2%) 06-26 18:28
Open: 0.85 Pre. Close: 0.83
High: 0.865 Low: 0.8284
Volume: 80,682 Market Cap: 40(M)
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.87 - 0.87 0.87 - 0.87
Low: 0.82 - 0.82 0.82 - 0.83
Close: 0.83 - 0.84 0.84 - 0.85

Technical analysis

as of: 2022-06-24 4:37:54 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.09     One year: 1.22
Support: Support1: 0.76    Support2: 0.63
Resistance: Resistance1: 0.93    Resistance2: 1.04
Pivot: 0.84
Moving Average: MA(5): 0.82     MA(20): 0.86
MA(100): 0.92     MA(250): 1.35
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 25     %D(3): 22.1
RSI: RSI(14): 42.3
52-week: High: 2.2  Low: 0.55
Average Vol(K): 3-Month: 527 (K)  10-Days: 147 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AIM ] has closed above bottom band by 48.0%. Bollinger Bands are 40% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sun, 26 Jun 2022
Democratic candidates for U.S. Senate take aim at Ron Johnson at state convention - Madison.com

Sun, 26 Jun 2022
Duluth takes aim at vacant buildings, citing public safety risk - Duluth News Tribune

Sun, 26 Jun 2022
Opinion: A shared aim, shared accountability in driving to ‘functional zero’ on homelessness - OregonLive

Sun, 26 Jun 2022
Period-Tracker Apps Aim for Anonymity Following Roe v. Wade Decision - The Wall Street Journal

Sun, 26 Jun 2022
White Sox aim to break 4-game slide, play the Orioles - FOX Sports

Sun, 26 Jun 2022
Diamondbacks aim to break losing streak in matchup with the Tigers - The Associated Press - en Español

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 47 (M)
% Held by Insiders 4.727e+007 (%)
% Held by Institutions 1.3 (%)
Shares Short 857 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.548e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -12
Return on Assets (ttm) 795.2
Return on Equity (ttm) -16
Qtrly Rev. Growth 127000
Gross Profit (p.s.) -0.02
Sales Per Share 0
EBITDA (p.s.) -0.31
Qtrly Earnings Growth -0.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -11 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales 275.18
Price to Cash Flow -0.57

Stock Dividends

Dividend 0
Forward Dividend 650280
Dividend Yield 0%
Dividend Pay Date 2019-06-10
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.